Mostrar el registro sencillo del ítem

Artículo

dc.creatorLabrador-Espinosa, Miguel Á.es
dc.creatorGrothe, Michel J.es
dc.creatorMacías-García, Danieles
dc.creatorJesús, Silviaes
dc.creatorAdarmes-Gómez, Astrides
dc.creatorMuñoz-Delgado, Lauraes
dc.creatorFernández-Rodríguez, Paulaes
dc.creatorMartín Rodríguez, Juan Franciscoes
dc.creatorGarcía-Solís, Davides
dc.creatorMir Rivera, Pabloes
dc.date.accessioned2024-06-18T12:13:43Z
dc.date.available2024-06-18T12:13:43Z
dc.date.issued2021
dc.identifier.citationLabrador-Espinosa, M.Á., Grothe, M.J., Macías-García, D., Jesús, S., Adarmes-Gómez, A., Muñoz-Delgado, L.,...,Mir Rivera, P. (2021). Levodopa-induced dyskinesia in Parkinson disease specifically associates with dopaminergic depletion in sensorimotor-related functional subregions of the striatum. Clinical nuclear medicine, 46 (6), e296-e306. https://doi.org/10.1097/RLU.0000000000003609.
dc.identifier.issn0363-9762es
dc.identifier.urihttps://hdl.handle.net/11441/160643
dc.description.abstractPurpose: To determine whether the development of levodopa-induced dyskinesia (LID) in Parkinson disease (PD) specifically relates to dopaminergic depletion in sensorimotor-related subregions of the striatum. Methods: Our primary study sample consisted of 185 locally recruited PD patients, of which 73 (40%) developed LID. Retrospective 123I-FP-CIT SPECT data were used to quantify the specific dopamine transporter (DAT) binding ratio within distinct functionally defined striatal subregions related to limbic, executive, and sensorimotor systems. Regional DAT levels were contrasted between patients who developed LID (PD + LID) and those who did not (PD-LID) using analysis of covariance models controlled for demographic and clinical features. For validation of the findings and assessment of the evolution of LID-associated DAT changes from an early disease stage, we also studied serial 123I-FP-CIT SPECT data from 343 de novo PD patients enrolled in the Parkinson Progression Marker's Initiative using mixed linear model analysis. Results: Compared with PD-LID, DAT level reductions in PD + LID patients were most pronounced in the sensorimotor striatal subregion (F = 5.99, P = 0.016) and also significant in the executive-related subregion (F = 5.30, P = 0.023). In the Parkinson Progression Marker's Initiative cohort, DAT levels in PD + LID (n = 161, 47%) were only significantly reduced compared with PD-LID in the sensorimotor striatal subregion (t = -2.05, P = 0.041), and this difference was already present at baseline and remained largely constant over time. Conclusion: Measuring DAT depletion in functionally defined sensorimotor-related striatal regions of interest may provide a more sensitive tool to detect LID-associated dopaminergic changes at an early disease stage and could improve individual prognosis of this common clinical complication in PD.es
dc.formatapplication/pdfes
dc.format.extent11 p.es
dc.language.isoenges
dc.publisherLippincott, Williams & Wilkinses
dc.relation.ispartofClinical nuclear medicine, 46 (6), e296-e306.
dc.subjectDopamine transporter (DAT)es
dc.subjectLevodopa-induced dyskinesiaes
dc.subjectParkinson’s diseasees
dc.subjectFP-CITes
dc.subjectSPECTes
dc.titleLevodopa-induced dyskinesia in Parkinson disease specifically associates with dopaminergic depletion in sensorimotor-related functional subregions of the striatumes
dc.typeinfo:eu-repo/semantics/articlees
dc.type.versioninfo:eu-repo/semantics/acceptedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Psicología Experimentales
dc.relation.publisherversionhttps://journals.lww.com/nuclearmed/fulltext/2021/06000/levodopa_induced_dyskinesia_in_parkinson_disease.26.aspxes
dc.identifier.doi10.1097/RLU.0000000000003609es
dc.journaltitleClinical nuclear medicinees
dc.publication.volumen46es
dc.publication.issue6es
dc.publication.initialPagee296es
dc.publication.endPagee306es
dc.description.awardwinningPremio Mensual Publicación Científica Destacada de la US. Facultad de Medicina

FicherosTamañoFormatoVerDescripción
Levodopa-induced dyskinesia in ...5.160MbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Este documento está protegido por los derechos de propiedad intelectual e industrial. Sin perjuicio de las exenciones legales existentes, queda prohibida su reproducción, distribución, comunicación pública o transformación sin la autorización del titular de los derechos, a menos que se indique lo contrario.